FGFR3-TACC3 fusion

News alerts, weekly reports and conference planners

Entrez ID:

2261; 10460

Related biomarkers:

‹

›

FGFR3-TACC3 fusion	Glioblastoma	FGFR3-TACC3 fusion	Glioblastoma	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3
FGFR3-TACC3 fusion	Gallbladder Cancer	FGFR3-TACC3 fusion	Gallbladder Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR3-TACC3 fusion	Urothelial Cancer	FGFR3-TACC3 fusion	Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR3-TACC3 fusion	Urothelial Cancer	FGFR3-TACC3 fusion	Urothelial Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR3-TACC3 fusion	Glioblastoma	FGFR3-TACC3 fusion	Glioblastoma	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR3-TACC3 fusion	Non Small Cell Lung Cancer	FGFR3-TACC3 fusion	Non Small Cell Lung Cancer	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3	infigratinib Sensitive: C3 – Early Trials infigratinib Sensitive : C3
FGFR3-TACC3 fusion	Non Small Cell Lung Cancer	FGFR3-TACC3 fusion	Non Small Cell Lung Cancer	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3	ponatinib Sensitive: C3 – Early Trials ponatinib Sensitive : C3
FGFR3-TACC3 fusion	Gastric Cancer	FGFR3-TACC3 fusion	Gastric Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR3-TACC3 fusion	Urothelial Cancer	FGFR3-TACC3 fusion	Urothelial Cancer	ARQ 087 Sensitive: C3 – Early Trials ARQ 087 Sensitive : C3	ARQ 087 Sensitive: C3 – Early Trials ARQ 087 Sensitive : C3
FGFR3-TACC3 fusion	Glioma	FGFR3-TACC3 fusion	Glioma	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4
FGFR3-TACC3 fusion	Adrenal Cortex Carcinoma	FGFR3-TACC3 fusion	Adrenal Cortex Carcinoma	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4
FGFR3-TACC3 fusion	Astrocytoma	FGFR3-TACC3 fusion	Astrocytoma	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4
FGFR3-TACC3 fusion	Endometrial Cancer	FGFR3-TACC3 fusion	Endometrial Cancer	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4
FGFR3-TACC3 fusion	Bladder Cancer	FGFR3-TACC3 fusion	Bladder Cancer	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4
FGFR3-TACC3 fusion	Urothelial Cancer	FGFR3-TACC3 fusion	Urothelial Cancer	atezolizumab Sensitive: C4 – Case Studies atezolizumab Sensitive : C4	atezolizumab Sensitive: C4 – Case Studies atezolizumab Sensitive : C4
FGFR3-TACC3 fusion	Lung Non-Small Cell Squamous Cancer	FGFR3-TACC3 fusion	Lung Non-Small Cell Squamous Cancer	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4
FGFR3-TACC3 fusion	Bladder Cancer	FGFR3-TACC3 fusion	Bladder Cancer	futibatinib Sensitive: D – Preclinical futibatinib Sensitive : D	futibatinib Sensitive: D – Preclinical futibatinib Sensitive : D
FGFR3-TACC3 fusion	Urothelial Cancer	FGFR3-TACC3 fusion	Urothelial Cancer	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D	erdafitinib Sensitive: D – Preclinical erdafitinib Sensitive : D
FGFR3-TACC3 fusion	Bladder Cancer	FGFR3-TACC3 fusion	Bladder Cancer	MPT0L145 Sensitive: D – Preclinical MPT0L145 Sensitive : D	MPT0L145 Sensitive: D – Preclinical MPT0L145 Sensitive : D
FGFR3-TACC3 fusion	Cholangiocarcinoma	FGFR3-TACC3 fusion	Cholangiocarcinoma	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D
FGFR3-TACC3 fusion	Urothelial Cancer	FGFR3-TACC3 fusion	Urothelial Cancer	dasatinib + infigratinib Sensitive: D – Preclinical dasatinib + infigratinib Sensitive : D	dasatinib + infigratinib Sensitive: D – Preclinical dasatinib + infigratinib Sensitive : D
FGFR3-TACC3 fusion	Bladder Cancer	FGFR3-TACC3 fusion	Bladder Cancer	AMB302 Sensitive: D – Preclinical AMB302 Sensitive : D	AMB302 Sensitive: D – Preclinical AMB302 Sensitive : D
FGFR3-TACC3 fusion	Glioblastoma	FGFR3-TACC3 fusion	Glioblastoma	AMB302 Sensitive: D – Preclinical AMB302 Sensitive : D	AMB302 Sensitive: D – Preclinical AMB302 Sensitive : D
FGFR3-TACC3 fusion	Lung Cancer	FGFR3-TACC3 fusion	Lung Cancer	LY3076226 Sensitive: D – Preclinical LY3076226 Sensitive : D	LY3076226 Sensitive: D – Preclinical LY3076226 Sensitive : D
FGFR3-TACC3 fusion	Bladder Cancer	FGFR3-TACC3 fusion	Bladder Cancer	LY3076226 Sensitive: D – Preclinical LY3076226 Sensitive : D	LY3076226 Sensitive: D – Preclinical LY3076226 Sensitive : D

FGFR3-TACC3 fusion

Associations